J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.BO)
INR 1522.05
(0.25%)
INR 1522.05
(0.25%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 236.4 Million INR | -94.07% |
| 2022 | 3.98 Billion INR | 1833.01% |
| 2021 | 206.17 Million INR | 301.01% |
| 2020 | 51.41 Million INR | 318.27% |
| 2019 | 12.29 Million INR | -65.14% |
| 2018 | 35.26 Million INR | -41.94% |
| 2017 | 60.73 Million INR | -29.44% |
| 2016 | 86.07 Million INR | 0.0% |
| 2015 | - INR | -100.0% |
| 2014 | 4 Million INR | -18.1% |
| 2013 | 4.88 Million INR | 124.45% |
| 2012 | 2.17 Million INR | -45.96% |
| 2011 | 4.02 Million INR | -96.78% |
| 2010 | 125.25 Million INR | -90.84% |
| 2009 | 1.36 Billion INR | -23.49% |
| 2008 | 1.78 Billion INR | -8.96% |
| 2007 | 1.96 Billion INR | 12.61% |
| 2006 | 1.74 Billion INR | 82.34% |
| 2005 | 956.25 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 236.4 Million INR | 0.0% |
| 2023 Q2 | 2.92 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 236.4 Million INR | -94.07% |
| 2023 Q1 | - INR | -100.0% |
| 2022 FY | 3.98 Billion INR | 1833.01% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 3.98 Billion INR | 0.0% |
| 2022 Q2 | 2.49 Billion INR | 0.0% |
| 2021 FY | 206.17 Million INR | 301.01% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 206.17 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 227.63 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 51.41 Million INR | 318.27% |
| 2020 Q4 | 51.41 Million INR | 0.0% |
| 2020 Q2 | 70.54 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 12.29 Million INR | -65.14% |
| 2019 Q2 | - INR | 0.0% |
| 2019 Q4 | 12.29 Million INR | 0.0% |
| 2019 Q3 | - INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2018 Q4 | 35.26 Million INR | 0.0% |
| 2018 FY | 35.26 Million INR | -41.94% |
| 2017 FY | 60.73 Million INR | -29.44% |
| 2016 FY | 86.07 Million INR | 0.0% |
| 2016 Q4 | - INR | 0.0% |
| 2015 FY | - INR | -100.0% |
| 2015 Q4 | - INR | 0.0% |
| 2014 FY | 4 Million INR | -18.1% |
| 2013 FY | 4.88 Million INR | 124.45% |
| 2012 FY | 2.17 Million INR | -45.96% |
| 2011 FY | 4.02 Million INR | -96.78% |
| 2010 FY | 125.25 Million INR | -90.84% |
| 2009 FY | 1.36 Billion INR | -23.49% |
| 2008 FY | 1.78 Billion INR | -8.96% |
| 2007 FY | 1.96 Billion INR | 12.61% |
| 2006 FY | 1.74 Billion INR | 82.34% |
| 2005 FY | 956.25 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 62.405% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 98.893% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -60.152% |
| Granules India Limited | 689.71 Million INR | 65.725% |
| Indoco Remedies Limited | 3.51 Billion INR | 93.279% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | -0.51% |
| Alkem Laboratories Limited | 400 Million INR | 40.9% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -6531.136% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -749.26% |
| Bajaj HealthCare Limited | 650.34 Million INR | 63.65% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 33.581% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 96.053% |
| Eris Lifesciences Limited | 6.54 Billion INR | 96.388% |
| FDC Limited | 2.46 Million INR | -9486.375% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 84.416% |
| Gufic Biosciences Limited | 1.53 Billion INR | 84.646% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -111.779% |
| Ipca Laboratories Limited | 5.8 Billion INR | 95.927% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -212.823% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 87.117% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 97.252% |
| Lupin Limited | 1.55 Billion INR | 84.776% |
| Mankind Pharma Limited | 248.67 Million INR | 4.937% |
| Medicamen Biotech Limited | 12.55 Million INR | -1782.915% |
| Medico Remedies Limited | 8.67 Million INR | -2626.015% |
| Megasoft Limited | 1.35 Billion INR | 82.58% |
| NATCO Pharma Limited | 53 Million INR | -346.038% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.048% |
| RPG Life Sciences Limited | -30.3 Million INR | 880.198% |
| Sigachi Industries Limited | 265.79 Million INR | 11.06% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -1677.444% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -11.322% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 19492.945% |
| Unichem Laboratories Limited | 382.22 Million INR | 38.151% |
| Wanbury Limited | 820 Million INR | 71.171% |
| Windlas Biotech Limited | 20.18 Million INR | -1071.457% |
| ZIM Laboratories Limited | 356 Million INR | 33.597% |
| Zydus Lifesciences Limited | 251 Million INR | 5.817% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -121.764% |
| Divi's Laboratories Limited | 20 Million INR | -1082.0% |
| Hester Biosciences Limited | 1.81 Billion INR | 86.995% |
| Procter & Gamble Health Limited | 68.8 Million INR | -243.605% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -1592.44% |
| Bal Pharma Limited | 363.82 Million INR | 35.024% |
| Strides Pharma Science Limited | 6.71 Billion INR | 96.48% |
| Venus Remedies Limited | 386.8 Million INR | 38.883% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -59000.0% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 83.151% |
| Shilpa Medicare Limited | 5.6 Billion INR | 95.78% |
| Aarti Drugs Limited | 2.75 Billion INR | 91.414% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 97.658% |
| Valiant Laboratories Limited | 746.63 Million INR | 68.338% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 77.662% |
| Themis Medicare Limited | 267.74 Million INR | 11.705% |
| Hikal Limited | 4.22 Billion INR | 94.409% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 98.526% |
| Sequent Scientific Limited | 1.42 Billion INR | 83.436% |
| Novartis India Limited | 50.7 Million INR | -366.272% |
| Wockhardt Limited | 8.91 Billion INR | 97.347% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.254% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | 47.374% |
| Morepen Laboratories Limited | 33.64 Million INR | -602.735% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -77.024% |